Business Description
Apimeds Pharmaceuticals Us Inc
NAICS : 325412
SIC : 2834
ISIN : US03771D1028
Total Employee Number:
7Description
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.26 | |||||
Equity-to-Asset | 0.9 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | -0.24 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -112.1 | |||||
3-Year EPS without NRI Growth Rate | -167.4 | |||||
3-Year FCF Growth Rate | -176.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 14.23 | |||||
9-Day RSI | 23.26 | |||||
14-Day RSI | 29.31 | |||||
3-1 Month Momentum % | -31.38 | |||||
6-1 Month Momentum % | -22.29 | |||||
12-1 Month Momentum % | -28.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.9 | |||||
Quick Ratio | 0.9 | |||||
Cash Ratio | 0.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.8 | |||||
Shareholder Yield % | -36.47 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -68.68 | |||||
ROA % | -62.46 | |||||
ROIC % | -39.19 | |||||
3-Year ROIIC % | -7.08 | |||||
ROC (Joel Greenblatt) % | -982.4 | |||||
ROCE % | -66.7 | |||||
Moat Score | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.07 | |||||
Price-to-Tangible-Book | 0.07 | |||||
EV-to-EBIT | -0.45 | |||||
EV-to-EBITDA | -0.46 | |||||
EV-to-FCF | -1.64 | |||||
Earnings Yield (Greenblatt) % | -222.22 | |||||
FCF Yield % | -101.07 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:APUS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Apimeds Pharmaceuticals Us Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.74 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 89.08 | ||
| 14-Day RSI | 29.31 | ||
| 14-Day ATR ($) | 0.169429 | ||
| 20-Day SMA ($) | 0.966278 | ||
| 12-1 Month Momentum % | -28.73 | ||
| 52-Week Range ($) | 0.6794 - 5.97 | ||
| Shares Outstanding (Mil) | 15.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Apimeds Pharmaceuticals Us Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Apimeds Pharmaceuticals Us Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 123 days | ||
| Second quarter earnings results for 2026 | 2026-08-31 | In 50 days | ||
| General meeting for 2026 | 2026-07-16 | In 4 days | ||
| First quarter earnings results for 2026 | 2026-05-26 | 1.50 (+9.49%) | ||
| Annual report for 2025 | 2026-05-04 | 1.88 (+0.00%) | ||
| 0.1:1 Stock Split | 2026-03-26 | 1.75 (+2.14%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 2.67 (+1.52%) | ||
| Second quarter earnings results for 2025 | 2025-08-19 | 1.75 (+6.06%) | ||
| First quarter earnings results for 2025 | 2025-05-20 | 1.79 (+8.48%) | ||
| Annual report for 2024 | 2025-04-15 | -- |
Show
Entries
Apimeds Pharmaceuticals Us Inc Frequently Asked Questions
What is Apimeds Pharmaceuticals Us Inc(APUS)'s stock price today?
The current price of APUS is $0.72. The 52 week high of APUS is $5.97 and 52 week low is $0.68.
When is next earnings date of Apimeds Pharmaceuticals Us Inc(APUS)?
The next earnings date of Apimeds Pharmaceuticals Us Inc(APUS) is 2026-08-31 Est..
Does Apimeds Pharmaceuticals Us Inc(APUS) pay dividends? If so, how much?
Apimeds Pharmaceuticals Us Inc(APUS) does not pay dividend.
Guru Commentaries on AMEX:APUS
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Apimeds Pharmaceuticals Us Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers